Strategic collaboration Partnership with Swiss Cancer Institute and ongoing INVINCIBLE-4 Phase 2/3 program present a strong entry point for co-development discussions, potential favorable reimbursement positioning, and access to a larger clinical network for joint trials and access to diverse patient populations.

Clinical momentum Active Phase 1/2 development of INT230-6 for multiple advanced solid tumors demonstrates a robust clinical pipeline and near-term opportunities to engage in investigator-initiated studies, site partnerships, and physician-facing educational outreach to drive trial enrollment.

Immunotherapy niche Intratumoral delivery platform plus non-covalent drug conjugation offers differentiating value in converting local tumor control into systemic immune responses, creating dialogue with hospitals and oncology networks seeking innovative, site-accessible therapies.

Funding signals Recent financing rounds and industry recognition ($3M direct financing, healthcare awards) indicate improving visibility and credibility, which can be leveraged to pursue strategic investors, grant programs, and sponsorships for expanded trials and manufacturing scale-up.

Operational footprint Small but focused team with Phase 2/3 collaboration potential aligns with outsourcing manufacturing partners, contract research organizations, and regional distributors to accelerate market access while maintaining synthetic and regulatory agility.